1. Birch JM. Epidemiology of paediatrick cancer.ln
Duncan J (ed) Recent Results in Cancer
Research,Vol 88: Paediatrick Oncology, pp 1-10.
Heidelberg: Springer-Verlag. 1983.
2. Philip T, Herve P, Racadot E, et al. Intensive
cytoreductive regimen and autologous bone marrow
transplantation in leukemias and solid tumours (a
review). Transplantation and Clinical Immunology,
14: 86-109, 1982.
3. Shpall EJ, Stemmer SM, Bearman SI, Jones RB.
Role of autotransplantation in treatment of other
solid tumors. Hematol Oncol Clin North Am. 7(3):
663-686, 1993.
4. Frei E & Canellos GP. Dose: a critical factor in
cancer chemotherapy. Am J Med. 69: 585-594,
1979.
5. Adkins DR, Irvin R, Kuhn J, et al. A phase I clinical
and pharmacological profile of dacarbazine with
autolog bone marrow transplantation in patients
with solid tumors. Invest New Drugs. 11(2-3): 169¬
179, 1993.
6. Bosly A, Guillaume T, Brice P, et al. Effects of
escalating doses of recombinant human IL-2 in
correcting functional T cell defects following
autologous bone marrow transplantation for
lymphomas and solid tumors. Exp Hematol. 20(8):
962-968, 1992.
7. Guillaume T, Sekhavat M, Rubinstein DB, et al.
Defective cytokine production following autologous
stem cell transplantation for solid tumors and
hematologic malignancies regardless of bone
marrow or peripheral origin and lack of evidence for
a role for IL-10 in delayed immune reconstitution.
Cancer Res. 54(14): 3800-3807, 1994.
8. Gallagher CJ, Gregory VM,.Jones AE, Stansfeld
AG, Richards MA, et al. Follicular Lymphoma:
Journal of Turgut Özal Medical Center 2(3): 1995 295
Solid tümörlerin tedavisinde
S Büyükberber ve ark.
Prognostic factors for response and survival. J Clin
Oncol. 4: 1470, 1986.
9. Rohatiner AZS, Cotter FE, Price CCA. et al. Ablative
therapy supported by autologous bone marrow
transplantation (ABMT) as consolidation of
remission in patients with follicular lymphoma. Proc
Am Soc Clin Oncol 8:266, 1989.
10. Colombat P, Desbois I, Biron P, et al. Results of
high dose chemotherapy with autologous bone
marrow transplantation in 16 cases of follicular
lymphomas. Exp Hematol. 17:585, 1989.
11. Freedman AS, Takvorian T, Ritz J, et al. Autologous
Bone Marrow Transplantation. Proceedings of the
Fourth International Symposium. Houston, The
University of Texas MD Anderson Cancer Center, p
327, 1989.
12. Bierman PJ, Vose JM, Kessinger A, et al. High dose
therapy with hemopoietic rescue for low-grade non-
Hodgkin lymphoma. Exp Hematol 17:585, 1989.
13. Freedman SA, Ritz J, Neuberg D, et al. Autologous
bone marrow transplantation in 69 patients with a
history of low grade B-Cell non-Hodgkin's
lymphoma. Blood. 77:2524, 1991.
14. Goldstone AH, Gribben JG, McMillan AK, Taghipour
G. The sixth report of the EBMTG registry of ABMT
in lymphomas. Bone Marrow Transplant. 4 (suppl.
2): 53, 1989 (abstr).
15. Vose JM, Armitage JO. Role of autologous bone
marrow transplantation in non-Hodgkin lymphomas.
Hematol Oncol Clin North Am. 7(3):577-590, 1993
16. Richel DJ, Van der Wall E, Slaper J, et al. Peripheral
blood stem cell mobilization and transplantation in
patients with malignant lymphomas and solid
tumors. Int J Artif Organs. 16(suppl 5):71-75, 1993.
17. Tura S, Mazza P, Charlizoni F, et al. High dose
therapy followed by autologous bone marrow
transplantation (ABMT) in previously untreated non-
Hodgkin's lymphoma. Scand J Hematol 37:317,
1986.
18 Gulati SC, Shank B, Black P, et al. Autologous bone
marrow transplantation for patients with poor
prognosis lymphoma. J Clin Oncol 6:1303, 1988.
19. Baro J, Richard C, Calavia JD, et al. Autologous
bone marrow transplantation as consolidation
therapy for non-Hodgkin's lymphoma patients with
poor prognostic features. Bone Marrow Transplant
8:283, 1991.
20. Philip T, Hartmann O, Biron P, et al. High-dose
therapy and autologous bone marrow transplantation
in partial remission after first-line induction therapy
for diffuse non-Hodgkin's lymphoma. J Clin Oncol
6:1118, 1988.
21. Armitage JO, Gingrich RD, Klassen LW, et al. Trial
of high dose cytarabine, cyclophosphamide, total
body irradiation and autologous bone marrow
transplantation for refractory lymphoma.Cancer
Treat Rep 70:871. 1986.
22. Philip T, Biron P, Maraninchi D, et al. Massive
chemotherapy with autologous bone marrow
transplantation in 50 cases of bad prognosis non-
Hodgkin's lymphoma. Br J Haemotol 60:599, 1985,
23. Philip T, Armitage JO, Spitzer G, et al. High-dose
therapy and autologous bone marrow transplantation
after failure of conventional chemotherapy in adults
with intermediate grade or high-grade non-
Hodgkin's lymphoma.N Engl J Med 316:1493, 1987.
24. Wilson WH, Jain V, Bryant G, et al. Phase I and II
study of high dose ifosfamide, carboplatin, and
etoposide with autologous bone marrow rescue in
lymphomas and solid tumors. J Clin Oncol. 10(11):
1712-1722, 1992.
25. Nachbaur D, Schwaighofer H, Thaler J, et al.
Innsbruck results of bone marrow transplantation in
treatment of hematologic neoplasms and solid
tumors. Wien Klin Wochenschr. 106(7): 201-207,
1994.
26. Takvorian T, Canellos CP, Ritz J, et al. Prolonged
disease free survival after autologous bone marrow
transplantation in patients with non-Hodgkin's
lymphoma with a poor prognosis. N Engl J Med
316:1499. 1987.
27. Philip T, Biron P, Philip I, et al. Massive Therapy
and autologous bone marrow transplantation in
paediatric and young adult Burkitt's lymphoma (30
courses on 28 patients: a 5 year experience). Eur J
Cancer Clin Oncol 22:1015, 1986.
28. Santaro A, Bonnadonna V, Bonnadonna G. Salvage
chemotherapy with ABVD in MOPP resistant
Hodgkin's disease Ann Intern Med 96:139, 1982.
29. Reece D, Barnett M,Connors J, et al. Augmented
cyclophosphamide, BCNU, and etoposide = CBV
and autologous bone marrow transplantation for
progressive Hodgkin's disease. Blood. 72(suppl
1):402 a, 1988.
30. Kessinger A, Nademanee A, Forman SJ, et al.
Autologous bone marrow transplantation for
Hodgkin's and non-Hodgkin's lymphoma. Hematol /
Oncol Clin North Am. 4(3) :577-585, 1990.
31. Jagannath S, Armitage JO, Dicke KA, et al.
Prognostic factorsfor response and survival after
high-dose cyclophosphamide, carmustine, and
etoposide with autologous bone marrow
transplantation for relapsed Hodgkin's disease. J
Clin Oncol 7:179, 1989.
32. Bierman PJ, Jagannath S, Dicke KA, et al. Highdose
cyclophosphamide, carmustine, and etoposide
(CBV) in 128 patients with Hodgkin's disease. Blood
72 (suppl 1):239 a, 1988.
33. Armitage JO. Bone marrow transplantation in the
treatment of patients with lymphoma. Blood
73:1749, 1989.
34. Phillips GL, Wolff SN, Herzig RH, et al. Treatment of
progressive Hodgkin's disease with intensive
chemoradiotherapy and autologous bone marrow
transplantation. Blood 73:2086, 1989.
35. Carella AM, Carlier P, Congiu D, et al. Autologous
bone marrow transplantation as adjuvant treatment
for high-risk Hodgkin's disease in first complete
remission after MOPP/ABVD protocol. Bone Marrow
Transplant 8:99, 1991.
36. Jagannath S, Barlogie B, Dicke K, et al. Autologous
bone marrow transplantation in multiple myeloma:
Identification of prognostic factors. Blood 76:1860,
1990
37. Bârlogie B, Alexanian R, Dicke K, et al. High-dose
thermoradiotherapy and autologous bone marrow
transplantation for resistant multiple myeloma. Blood
70:869, 1987.
296 Turgut Özal Tıp Merkezi Dergisi 2(3): 1995
Bone marrow transplantation ... ' S Büyükberber et al.
38. Frei E, Arıtman K, Teicher B, et al. Bone marrow autotransplantation for solid tumors-prospects. J Clin Oncol 7:515, 1989.
39. Shpall EJ, Jones RB, Bearman S. High-dose therapy with autologous bone marrow transplantationfor the treatment of solid tumors. Curr Opin Oncol. 6(2): 135-138, 1994.
40. Bowers C, Adkins D, Dunphy F, et al. Dose escalation of mitoxantrone given with thiotepa and autologous bone marrow transplantation for metastatic breast cancer. Bone Marrow Transplant. 12(5): 525-530, 1993.
41. Pico JL, Beaujean F, Debre M, et al. High-dose chemotherapy with autologous bone marrow transplantation in small cell carcinoma of the lung in relapse. Proc Am Soc Clin Oncol. 2:206, 1983 (abstr).
42. Rushing DA, Baldauf MC, Gehlsen JA, et al. High-dose BCNU and autologous bone marrow reinfusion in the treatment of refractory or relapsed small cell carcinoma of the lung. Proc Am Soc Clin Oncol. 3:217, 1984 (abstr).
43. Wolff SN, Herzig RH, Fay JW, et al. High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group. J Clin Oncol. 7:245, 1989.
44. Mulder POM, Willemse PHB, Aalders JG, et al. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer. Eur J Cancer Clin Oncol 25:645, 1989.
45. Menichella G, Pierelli L, Foddai ML, et al. Autologous blood stem cell harvesting and transplantation in patients with advanced ovarian cancer. Br J Haematol. 79:444, 1991.
46. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer - A phase l/ll trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 7:932, 1989.
47. Rosti G, Albertazzi L, Tienghi A, et al. An Italian experience of high-dose chemotherapy and autologous bone marrow transplantation in germ cell tumors.Suggestions for future direction. Leuk Lymphoma. 7 Suppl: 59-63, 1992.
48. Chevreau C, Droz JP, Pico JL, et al. Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ-cell tumors. Preliminary result of a French randomized trial. Eur Urol. 23(1): 213-218, 1993.
49. Pinkerton R, Philip T, Bouffet E, et al. Autologous bone marrow transplantation in paediatric solid tumours. Clin Haematol 15:187, 1986.
50. Rill DR, Santana VM, Roberts WM, et al. Direct cemonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 84(2): 380¬383, 1994.
51. Hartmann O, Kalifa C, Beaujean F, et al. Treatment of advanced neuroblastoma with two consecutive high-dose chemotherapy regimens and ABMT. In Evans AE, D'Angio GJ & Seeger RC (eds) Advances in Neuroblastoma Research. New York: Alan R. Liss,pp:565-568, 1985.
52. Philip T, Bernard JL, Zucker JM, et al. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: An unselected group of stage IV patients over 1 year of age. J Clin Oncol 5:266, 1987.
53. Dini G, Lonino E, Garaventa A, et al. Myeloablative Therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: Report of 34 cases. J Clin Oncol 9:962, 1991.
54. Shuster JJ, Cantor AB, McWilliams N, et al. The prognostic significiance of autologous bone marrow transplant in advanced neuroblastoma. J Clin Oncol 9:1045, 1991.
55. Dominici C, Deb G, Angioni A, et al. Peripheral blood stem cells in children with solid tumors. Part II. Immunocytologic detection of tumor cells in bone marrow and peripheral blood stem cell harvests. Anticancer Res. 13(6B): 2573-2575, 1993.
56. Graham ML, Yeager AM, Leventhal BG, et al. Treatment of recurrent and refractory pediatric solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue. J Clin Oncol. 10(12): 1857-1864, 1992.
57. Laws HJ, Dilloo D, Hanenberg H,et al. Immune stimulation with IL-2 after autologous stem cell transplantation in children and adolescents with solid tumors. Klin Padiatr. 205(4): 257-263, 1993.
Thank you for copying data from http://www.arastirmax.com
